FLATLEY JAY T 4

What Happened

• Jay T. Flatley, a director of Denali Therapeutics (DNLI), received equity awards on 2026-06-03 consisting of 6,408 RSUs and 19,226 derivative awards (total 25,634 units). The grants were reported with $0 cash paid (typical for RSU/award grants).

Key Details

• Transaction date: 2026-06-03; filing date: 2026-06-05 (filed two days after the transaction — appears timely).
• Reported amounts: 6,408 shares (RSUs) + 19,226 derivative units = 25,634 total.
• Price: $0.00 per share (award/grant), total cash paid $0.
• Ownership after transaction: not specified in the provided excerpt of the filing.
• Footnotes: F1–F4 describe the award mechanics — each unit is represented by an RSU/contingent right to one share; 100% of the RSUs vest upon the earlier of (i) one year after grant or (ii) the day before the issuer’s next annual meeting. F2 notes 6,408 are unvested RSUs; F3 states shares are held of record by The Flatley Family Trust.

Context

• These are award grants (not open-market purchases or sales). RSUs/derivative awards give the holder a future right to receive shares upon vesting and do not indicate an immediate cash investment or sale. For retail investors, such awards are routine compensation for insiders and should be viewed as compensation-related rather than a direct market sentiment signal.